Skip to main content
Top
Published in: Malaria Journal 1/2019

Open Access 01-12-2019 | Chloroquin | Research

Utilization patterns of malaria chemoprophylaxis among Tanzanian children attending sickle cell clinic in Dar es Salaam tertiary hospitals

Authors: Esther J. Ndegeulaya, George M. Bwire, Raphael Z. Sangeda, Doreen Mloka, Faustine Tungaraza, Augustino S. Kahere, Fidelis F. Manyaki, Fatuma F. Felician, Manase Kilonzi, Wigilya P. Mikomangwa, Hamu J. Mlyuka, Alphonce I. Marealle, Ritah Mutagonda, Liberata Mwita, Kennedy D. Mwambete

Published in: Malaria Journal | Issue 1/2019

Login to get access

Abstract

Background

Malaria is among the leading cause of infection in individuals with sickle cell disease (SCD) living in sub-Saharan Africa, including Tanzania. However, after 2005 the standard treatment guidelines (STGs) on malaria chemoprevention for SCD patients were non-existent, and at present no medicine is recommended for SCD patients. Since several anti-malarials have been approved for the treatment of malaria in Tanzania, it is important to establish if there is a continued use of chemoprevention against malaria among SCD children.

Methods

A cross-sectional, hospital-based study was conducted between January and June 2019 at tertiary hospitals in Dar es Salaam. Data were collected using a semi-questionnaire and analysed using SPSS software version 25. The descriptive statistics were summarized using proportions, while factors associated with the use of chemoprophylaxis were analysed using multivariate logistic regression. Statistical significance of p < 0.05 was accepted.

Results

A total of 270 SCD children were involved. The median age of SCD children was 6 years (interquartile range (IQR): 3–11 years). Of 270 SCD children, 77% (number (n) = 218) of children with SCD had not been diagnosed with malaria in the previous year, whereas 12.6% (n = 34) of children were admitted because of malaria in the previous year. Regarding the use of chemoprophylaxis in SCD children, 32.6% (n = 88) of parents were aware that, chemoprophylaxis against malaria is recommended in SCD children. Of the 270 participants, 17% (n = 46) were using malaria chemoprophylaxis. A majority used artemisinin combination therapy (ACT), 56.8% (n = 26). Of 223 parents who did not give chemoprophylaxis, the majority (n = 142, 63.7%) indicated unavailability at clinics as the reason. Children whose parents were primary level educated were 9.9 times more likely to not use chemoprophylaxis (adjusted odds ratio (AOR); 9.9, 95% CI 1.8–56.5, P = 0.01) compared to those whose parents had tertiary education.

Conclusion

Despite the lack of STGs, a small proportion of children with SCD were using malaria chemoprophylaxis where the majority used ACT, i.e., dihydroartemisinin-piperaquine.
Literature
1.
go back to reference WHO. World Malaria Report 2017, Geneva, World Health Organization, 2017. WHO. World Malaria Report 2017, Geneva, World Health Organization, 2017.
2.
go back to reference Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN. Global burden of sickle cell anaemia in children under five, 2010–2050: modelling based on demographics, excess mortality, and interventions. PLoS Med. 2013;10:e1001484.CrossRef Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN. Global burden of sickle cell anaemia in children under five, 2010–2050: modelling based on demographics, excess mortality, and interventions. PLoS Med. 2013;10:e1001484.CrossRef
3.
go back to reference Piel FB, Patil AP, Howes RE, Nyagiri OA, Gething PW, Dewi M. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model- based map and population estimates. Lancet. 2013;381:142–51.CrossRef Piel FB, Patil AP, Howes RE, Nyagiri OA, Gething PW, Dewi M. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model- based map and population estimates. Lancet. 2013;381:142–51.CrossRef
4.
go back to reference Nkya S, Mtei L, Soka D, Mdai V, Mwakale PB, Mrosso P, et al. Newborn screening for sickle cell disease: an innovative pilot program to improve child survival in Dar es Salaam Tanzania. Int Health. 2019;11:589–95.CrossRef Nkya S, Mtei L, Soka D, Mdai V, Mwakale PB, Mrosso P, et al. Newborn screening for sickle cell disease: an innovative pilot program to improve child survival in Dar es Salaam Tanzania. Int Health. 2019;11:589–95.CrossRef
5.
go back to reference Makani J, Komba AN, Cox SE, Oruo J, Mwamtemi K, Kitundu J, et al. Malaria in patients with sickle cell anemia: burden, risk factors, and outcome at the outpatient clinic and during hospitalization. Blood. 2010;115:215–20.CrossRef Makani J, Komba AN, Cox SE, Oruo J, Mwamtemi K, Kitundu J, et al. Malaria in patients with sickle cell anemia: burden, risk factors, and outcome at the outpatient clinic and during hospitalization. Blood. 2010;115:215–20.CrossRef
6.
go back to reference Olaosebikan R, Ernest K, Bojang K, Mokuolu O, Rehman AM, Affara M, et al. A randomized trial to compare the safety, tolerability, and effectiveness of 3 antimalarial regimens for the prevention of malaria in Nigerian patients with sickle cell disease. J Infect Dis. 2015;212:617–25.CrossRef Olaosebikan R, Ernest K, Bojang K, Mokuolu O, Rehman AM, Affara M, et al. A randomized trial to compare the safety, tolerability, and effectiveness of 3 antimalarial regimens for the prevention of malaria in Nigerian patients with sickle cell disease. J Infect Dis. 2015;212:617–25.CrossRef
7.
go back to reference Eridani S. Sickle cell protection from malaria: a review. Hematol Rep. 2011;3:e24.CrossRef Eridani S. Sickle cell protection from malaria: a review. Hematol Rep. 2011;3:e24.CrossRef
8.
go back to reference Makani J, Soka D, Rwezaula S, Krag M, Mghamba J, Ramaiya K, et al. Health policy for sickle cell disease in Africa: experience from Tanzania on interventions to reduce under-five mortality. Trop Med Int Health. 2015;20:184–7.CrossRef Makani J, Soka D, Rwezaula S, Krag M, Mghamba J, Ramaiya K, et al. Health policy for sickle cell disease in Africa: experience from Tanzania on interventions to reduce under-five mortality. Trop Med Int Health. 2015;20:184–7.CrossRef
9.
go back to reference Aneni EC, Hamer DH, Gill CJ. Systematic review of current and emerging strategies for reducing morbidity from malaria in sickle cell disease. Trop Med Int Health. 2013;18:313–27.PubMed Aneni EC, Hamer DH, Gill CJ. Systematic review of current and emerging strategies for reducing morbidity from malaria in sickle cell disease. Trop Med Int Health. 2013;18:313–27.PubMed
10.
go back to reference National Malaria Contol Programme. National guidelines for malaria diagnosis and treatment Malar Control Ser No 11. Tanzania: Dar es Salaam; 2005. p. 2006. National Malaria Contol Programme. National guidelines for malaria diagnosis and treatment Malar Control Ser No 11. Tanzania: Dar es Salaam; 2005. p. 2006.
11.
go back to reference National Bureau of Statistics. Tanzania Malaria Indicator Survey 2017. Dar es Salaam, Tanzania. Accessed November 20, 2019. National Bureau of Statistics. Tanzania Malaria Indicator Survey 2017. Dar es Salaam, Tanzania. Accessed November 20, 2019.
12.
go back to reference Standard Treatment Guidelines & National Essential Medicines List Tanzania Mainland. 2017. Dar es Salaam, Tanzania. Accessed November 20, 2019. Standard Treatment Guidelines & National Essential Medicines List Tanzania Mainland. 2017. Dar es Salaam, Tanzania. Accessed November 20, 2019.
14.
go back to reference Bwire GM, Mwambete KD. Immunological perspectives of sub-Saharan populations under prophylaxis against malaria. J. Immunol Inflamm Dis Ther. 2019;3:1–3. Bwire GM, Mwambete KD. Immunological perspectives of sub-Saharan populations under prophylaxis against malaria. J. Immunol Inflamm Dis Ther. 2019;3:1–3.
Metadata
Title
Utilization patterns of malaria chemoprophylaxis among Tanzanian children attending sickle cell clinic in Dar es Salaam tertiary hospitals
Authors
Esther J. Ndegeulaya
George M. Bwire
Raphael Z. Sangeda
Doreen Mloka
Faustine Tungaraza
Augustino S. Kahere
Fidelis F. Manyaki
Fatuma F. Felician
Manase Kilonzi
Wigilya P. Mikomangwa
Hamu J. Mlyuka
Alphonce I. Marealle
Ritah Mutagonda
Liberata Mwita
Kennedy D. Mwambete
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2019
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/s12936-019-3029-y

Other articles of this Issue 1/2019

Malaria Journal 1/2019 Go to the issue